These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dopaminergic receptors: a new antihypertensive mechanism. Velasco M; Contreras F; Cabezas GA; Bolívar A; Fouillioux C; Hernández R J Hypertens Suppl; 2002 Jun; 20(3):S55-8. PubMed ID: 12184056 [TBL] [Abstract][Full Text] [Related]
3. The dopaminergic system in hypertension. Zeng C; Zhang M; Asico LD; Eisner GM; Jose PA Clin Sci (Lond); 2007 Jun; 112(12):583-97. PubMed ID: 17492945 [TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of dopamine modulators on the cardiovascular and renal systems. Doggrell SA Expert Opin Investig Drugs; 2002 May; 11(5):631-44. PubMed ID: 11996645 [TBL] [Abstract][Full Text] [Related]
5. Enhanced angiotensin II-induced activation of Na+, K+-ATPase in the proximal tubules of obese Zucker rats. Shah S; Hussain T Clin Exp Hypertens; 2006 Jan; 28(1):29-40. PubMed ID: 16443562 [TBL] [Abstract][Full Text] [Related]
6. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Vogt B; Bochud M; Burnier M Semin Nephrol; 2007 Sep; 27(5):529-37. PubMed ID: 17868790 [TBL] [Abstract][Full Text] [Related]
7. Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats. Maeda C; Schaan B; Oliveira E; Oliveira V; De Angelis K; Irigoyen M Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):574-80. PubMed ID: 17581211 [TBL] [Abstract][Full Text] [Related]
8. Dopamine receptors in hypertension. Bek MJ; Eisner GM; Felder RA; Jose PA Mt Sinai J Med; 2001 Nov; 68(6):362-9. PubMed ID: 11687863 [TBL] [Abstract][Full Text] [Related]
9. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor. Dobrian AD Vascul Pharmacol; 2006 Jul; 45(1):36-45. PubMed ID: 16716756 [TBL] [Abstract][Full Text] [Related]
10. [Obesity and hypertension]. Verdecchia P; Trimarco B G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):54S-59S. PubMed ID: 18773751 [TBL] [Abstract][Full Text] [Related]
12. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension. Georgescu A; Popov D; Dragan E; Dragomir E; Badila E Eur J Pharmacol; 2007 Sep; 570(1-3):149-58. PubMed ID: 17612521 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of Ang II and renal sympathetic nerve influence dopamine-and isoprenaline-induced renal haemodynamic changes in normal Wistar-Kyoto and spontaneously hypertensive rats. Abdulla MH; Sattar MA; Abdullah NA; Hazim AI; Anand Swarup KR; Rathore HA; Khan MA; Johns EJ Auton Autacoid Pharmacol; 2008 Oct; 28(4):95-101. PubMed ID: 18778332 [TBL] [Abstract][Full Text] [Related]
14. Dopamine acutely decreases type 3 Na(+)/H(+) exchanger activity in renal OK cells through the activation of protein kinases A and C signalling cascades. Gomes P; Soares-da-Silva P Eur J Pharmacol; 2004 Mar; 488(1-3):51-9. PubMed ID: 15044035 [TBL] [Abstract][Full Text] [Related]
15. Impact of obesity and insulin resistance on vasomotor tone: nitric oxide and beyond. Stepp DW Clin Exp Pharmacol Physiol; 2006; 33(5-6):407-14. PubMed ID: 16700872 [TBL] [Abstract][Full Text] [Related]
16. The heart in obesity-hypertension. Morse SA; Bravo PE; Morse MC; Reisin E Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):647-58. PubMed ID: 16076275 [TBL] [Abstract][Full Text] [Related]